• Advanced breast cancer
• Advanced renal cell carcinoma
• Advanced pancreatic neuroendocrine tumours
• Treatment of subependymal giant cell astrocytoma

It contains the active ingredient Suregraft 0.25mg Tablet, which inhibits the activity of a protein called mammalian target of rapamycin (mTOR), which regulates cell growth. This drug can slow the growth of abnormal cancer cells by blocking the mTOR protein. Suregraft 0.25mg Tablet helps to reduce the size of tumours and improve outcomes in patients.

Inform your healthcare provider about all the medicines you take, including prescription medications, over-the-counter medications, nutritional or vitamin supplements, and herbal products. Certain medications may interact with Suregraft 0.25mg Tablet and reduce effectiveness by causing undesirable side effects.

• Store Suregraft 0.25mg Tablet in the original package at room temperature (20°C to 25°C).
• Do not freeze.
• Keep it out of reach from children.

Your doctor will decide the dose and duration of Suregraft 0.25mg Tablet based on the disease condition and other factors. Always take this medicine as prescribed by your doctor. Take the tablet at the same time everyday, with or without food. Do not chew, crush, or break the tablet. Swallow the whole tablet with water. If you forgot to take the tablet, simply take your next dose at the scheduled time. Do not take a double dose to make up for a forgotten dose.

Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.

Serious:

• Difficulty breathing, or swallowing
• Swelling of face, lips, tongue, throat
• Severe itching, red rash, raised bumps

Common:

• Infection (chills, increased temperature)
• Coughing
• Wheezing
• Excessive thirst
• High urine output or severely decreased urine output
• Tiredness
• Bleeding
• Increased appetite with weight loss

Suregraft 0.25mg Tablet have the tendency to cause harm to unborn foetus. Inform your healthcare provider before starting this treatment if you are pregnant, or have a partner who can become pregnant. Your health care provider will conduct a pregnancy test before you start treatment with Suregraft 0.25mg Tablet. Discuss effective birth control methods with your healthcare provider and use them during treatment and for 8 weeks after your last dose. It is not known if Suregraft 0.25mg Tablet passes into the breast milk. Hence, it is not recommended to breastfeed during this treatment. Occurrence of mouth ulcers or sores are pretty common during this treatment, so your healthcare provider will prescribe a mouthwash. Use the mouthwash as recommended which helps prevent and manage the symptoms.

1. Accord Healthcare Limited, Electronic medicines compendium (EMC), [ Revised on Oct 2020] [ Accessed on 18th March 2023], https://www.medicines.org.uk/emc/files/pil.11084.pdf
2. Jan Hasskarl; Everolimus; Recent Results in Cancer Research; Published on 2018; Accessed on 18/03/2023; https://pubmed.ncbi.nlm.nih.gov/30069763/
3. Novartis Pharmaceuticals Corporation, US Food and Drug Administration, [ Revised on July 2012] [ Accessed on 18th March 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf
4. Goodman & Gilman’s, The Pharmacological Basis of Therapeutics, Targeted therapy: tyrosine kinase inhibitors, monoclonal antibodies, and cytokines, 12th edition, 2011, 1743.
5. KD Tripathi, Essentials of Medical Pharmacology, Immunosuppressant drugs, 7th edition, 2013, 878 - 882.